Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a company that focused on the efficacy of current medications, and is developing products that utilize their proprietary Depofoam® technology to better control the release of drugs into the body. Its FDA-approved product DepoCyt(e)® is one example. This is a sustained-release liposomal formulation of the drug cytarabine, which is used for the treatment of myphomatous meningitis (a deadly cancer of the immune system).
EXPAREL is Pacira’s big take on improving postoperative pain treatment. The drug is a bupivacaine injection (a local analgesic commonly used in postsurgical care for patients), but the difference is that the bupivacaine is encapsulated in DepoFoam. This has shown to be effective in prolonging the painkilling effects of this analgesic by up to ten times or more.
Pacira is hoping to meet an unmet demand for non-opioid post-surgical analgesics. EXPAREL will deliver an extremely long-lasting dose of bupivacaine; which should not only reduce the amount of discomfort patients suffer shortly after surgical procedures, but will reduce the time that patients spend on opioid medications as well.
Pacirca filed its NDA for EXPAREL in September 2010, which was officially accepted at the end of that year. The FDA has approved EXPAREL, which should be a big catalyst for the stock since EXPAREL is the flagship product of the company.
Prior to some presentations earlier in October, Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. said: "We look forward to sharing new comparative data highlighting the pain control advantages that EXPAREL offers, as well as pharmacokinetic data, with the pharmacy and anesthesiology communities, who we believe will find great utility in EXPAREL should it be approved later this year."
EXPAREL is designed to extend the duration of analgesia provided by the commonly used local analgesic, bupivacaine. Based on clinical trial data, EXPAREL provides continuous and extended postsurgical analgesia for up to 72 hours*, compared with bupivacaine’s analgesic timeline of 7 hours or less**. Pacira believes EXPAREL will address a significant unmet medical need for a long-acting non-opioid postsurgical analgesic. Pacira believes that the utilization of EXPAREL in the armamentarium of post operative analgesics may reduce the dependence on opioid use in the post operative setting and delay the time to first opioid use so that oral rather than parenteral opioids can be used. This may:
- Result in improved patient satisfaction and outcomes;
- Minimize breakthrough episodes of pain and significantly reduce the consumption of supplemental opioid medications and;
- Simplify postsurgical pain management and reduce hospital cost and staff time on non-patient care, monitoring of infusion pumps, catheters, leading to improved hospital economics
A look at the stock chart shows the stock is looking to break past a level of key resistance at the $10.98 level with some support at the $10.27 level.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. This is an authorized repost of the original article, which can be found here.